상피성 난소암 환자에서 혈청 내 p53 자가 항체 발현과 예후평가와의 관계
The relationship between serum p53 autoantibodies and tic relevance of epithelial ovarian cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The aim of this study was to determine whether a significant in preoperative serum p53 autoantibodies in epithelial ovarian cancer. Methods: Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital -based retrospective study, preoperative sera from 17 patients with epithelial ovarian cancer and 15 patients with benign tumors of the ovaries, 15 healthy women were studies. Results: The prevalence of p53 AAb in patients with epithelial ovarian cancer was 35.3% (6/17). No p53 AAb were found in patients with benign tumors and healthy women. Presence of p53 AAb positively correlated with older age, poor response of chemotherapy. But the differences in the tumor stage, grade, poor progression free survival rate were not statistically significant. Conclusions: The assessment of preoperative serum p53 AAb seems to have a limited clinical value in the epithelial ovarian cancer.
Abstract
Objective: The aim of this study was to determine whether a significant in preoperative serum p53 autoantibodies in epithelial ovarian cancer. Methods: Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital -based retrospective study, preoperative sera from 17 patients with epithelial ovarian cancer and 15 patients with benign tumors of the ovaries, 15 healthy women were studies. Results: The prevalence of p53 AAb in patients with epithelial ovarian cancer was 35.3% (6/17). No p53 AAb were found in patients with benign tumors and healthy women. Presence of p53 AAb positively correlated with older age, poor response of chemotherapy. But the differences in the tumor stage, grade, poor progression free survival rate were not statistically significant. Conclusions: The assessment of preoperative serum p53 AAb seems to have a limited clinical value in the epithelial ovarian cancer.
참고문헌 (24)
- Akahira JI, "Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study", Gynecol Oncol, 81, pp.398~403 (2001)
- Boring CC, "Cancer statistics 1994", CA Cancer J Clin, 44, pp.7~26 (1994)
- Rao BR, "Endocrine factors in common epithelial ovarian cancer", Endocr Rev, 112, pp.14~26 (1991)
- Risch HA, "Hormonal etiology of epithelial ovarian cancer, with a hypothesis concering the role of androgens and progesterone", J Natl Cancer Inst, 90, pp.1774~1786 (1998)
- Parker SL, "Cancer statistics 1996", CA Cancer J Clin, 46, pp.5~27 (1996)
- Landis SH, "Cancer statistics, 1999", CA Cancer J Clin, 49, pp.8~31 (1999)
- Parkin DM, "Global cancer statistics", CA Cancer J Clin, 49, pp.33~64 (1999)
- Bishop JM, "Viral oncogenes", Cell, 42, pp.23~38 (1985)
- Chang F, "Tumourigenesis associated with the p53 tumour suppressor gene", Br J cancer, 68, pp.653~661 (1993)
- Greenblatt MS, "Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis", Cancer Res, 54, pp.4855~4878 (1994)
- Wen WH, "p53 mutations and expression in ovarian cancers: correlation with overall survival", Int J Gynecol Pathol, 18, pp.29~41 (1999)
- Crawford LV, "Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer", Int J Cancer, 30, pp.403~408 (1982)
- Goh HS, "p53 and behavior of colorectal cancer", Lancet, 344, pp.233~234 (1994)
- Kressner U, "Prognostic value of p53 gentetic changes in colorectal cancer", J Clin Oncol, 17, pp.593~599 (1999)
- Benhatter J, "p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal canrcinoma", Int J Cancer, 69, pp.190~192 (1996)
- Belluco C, "p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastasis", J Clin Oncol, 14, pp.2696~2701 (1996)
- Gadducci A, "Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer", Gyncologic Oncology, 72, pp.76~81 (1999)
- Angelopoulou K, "Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cnacer", Eur J Cancer, 33, pp.115~121 (1997)
- Vogl FD, "p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells", Oncology, 57, pp.324~329 (1999)
- Caron de Fromentel C, "Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma", Int J Cancer, 39, pp.185~189 (1987)
- Rodrigues NR, "p53 mutation in colorectal cancer", Proc Natl Acad Sci USA, 87, pp.7555~7559 (1990)
- Wynford-Thomas D, "p53 in tumour pathology: can we trust immunocytochemistry?", J Pathol, 166, pp.329~330 (1992)
- Righetti SC, "A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma", Cancer Res, 56, pp.689~693 (1996)
- Kohler MF, "Mutation and overexpression of p53 in early-stage epithelial ovarian cancer", Obstet Gynecol, 81, pp.643~650 (1993)